-- Study Primary Endpoint Was Not Met; Improvement in Multiple Measures of Fibrosis and Liver Injury Was Observed with Investigational Firsocostat and Cilofexor -- Gilead Sciences, Inc. (NASDAQ:GILD) ...
SINGAPORE, Dec. 8, 2024 /PRNewswire/ -- A newly published collaborative study [1] in the Journal of Hepatology, featuring HistoIndex – a global leader in stain-free digital pathology solutions for ...
SEONGNAM, South Korea, Nov. 7, 2022 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis and inflammation, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback